Psychiatr. pro Praxi, 2002; 4: 177-179

Buspiron a jeho využitie v ovplyvnení symptómov a prejavov generalizovanej úzkosti

MUDr. Radovan Vaškovský
Psychiatrické oddelenie, Fakultná nemocnica Nitra

Published: December 31, 2002  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vaškovský R. Buspiron a jeho využitie v ovplyvnení symptómov a prejavov generalizovanej úzkosti. Psychiatr. praxi. 2002;3(4):177-179.

Príspevok sa zaoberá sledovaním účinnosti a efektívnosti liečby nebenzodiazepínovým anxiolytikom - buspironom v liečbe generalizovanej úzkostnej poruchy v 12týždňovom sledovaní ambulantných pacientov. Výsledky naznačujú jeho dobrý farmakologický profil v ovplyvnení viacerých symptómov anxiety, a preto sa javí ako vhodný preparát pre dlhodobú liečbu pacientov s generalizovanou úzkostnou poruchou.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cohn JB, Rickels K. A pooled, double-blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety. Curr Med Res Opin 1989; 11: 304. Go to original source... Go to PubMed...
    2. Eison AS, Temple DL Jr. Buspirone: Review of its pharmacology and current perspectives on its mechanism of action. Amer J Med 1986; 80 (Suppl. 3B): 1-9. Go to original source... Go to PubMed...
    3. Enkelman R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 1991; 105: 428-432. Go to original source... Go to PubMed...
    4. Feighner JP. Buspirone in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 1987; 48, 12(Suppl.): 3-6.
    5. Feighner JP, Cohn JB. Analysis of individual symptoms in generalized anxiety: a pooled, multistudy, double-blind evaluation of buspirone. Neuropsychobiology 1989; 21: 124-130. Go to original source... Go to PubMed...
    6. Gelenberg AJ. Academic Highlights - buspirone: Seven years update. J Clin Psychiatry 1994; 55: 222-229.
    7. Goldberg HL, Pinnerty RJ. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Amer J Psychiatry 1997; 136: 1184-1187. Go to original source...
    8. Jann MW. Buspirone: An update on a unique anxiolytic agent. Pharmacotherapy 1988; 8, 2: 100-116. Go to original source... Go to PubMed...
    9. Laakman G, Schule C, Lorkowski G, et al. Buspirone and lorazepam in the treatment of generalized anxiety disorders in outpatients. Psychopharmacology (Berl) 1998; 136, 4: 357-366. Go to original source... Go to PubMed...
    10. Lader M. Psychological effect of buspirone. J Clin Psychiatry 1982; 43, 12, (Sec. 2): 62-67.
    11. Mattila M, Seppala T, Mattila MJ. Combined effects of buspirone and diazepam on objektive and subjektive tests on performance in healthy volunters. Clin Pharmacol Ther 1986; 40: 620-626. Go to original source... Go to PubMed...
    12. Moskowitz H, Smiley A. Effects of chronically administered buspirone and diazepam on driving-related skills performance. J Clin Psychiatry 1982; 43: 45-55.
    13. New JS. The discovery and development of buspirone: a new approach to the treatment of anxiety. Med res rev 1990; 101: 283-326. Go to original source... Go to PubMed...
    14. Newton RS, Marunycz JD, Alderdice MT, et al. Review of the side-effect profile of buspirone. Amer J Med 1986; 80 (Suppl 3B): 17-21. Go to original source... Go to PubMed...
    15. Rickels K. Buspirone in clinical practice. J Clin Psychiatry 1990; 51 (9 suppl); 51-54.
    16. Rickels K, Schweizer E. The clinical course and long-term management of generalized anxiety disorder. J Clin Pharmacol 1990; 10: 101S-110S. Go to original source... Go to PubMed...
    17. Rickels K, DeMartinis N, Garcia-Espana E, et al. Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long term benzodiazepine therapy. Amer J Psychiatry 2000; 157, 12: 1973-1979. Go to original source... Go to PubMed...
    18. Schneider LS. Overview of generalized anxiety disorder in the elderly. J Clin Psychiatry 1996; 57(suppl): 34-45.
    19. Sramek JJ, Frankiewics EJ, Cutler NR. Efficacy and safety of two dosing regimen in the treatment of outpatients with persistent anxiety. Clin Ther 1997; 19, 23: 498-506. Go to original source... Go to PubMed...
    20. Sramek JJ, Tansman M, Suri A, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry 1996; 57, 7: 287-291.
    21. Steinberg JR. Anxiety in elderly patients: a comparison of azapirones and benzodizepines. Drugs Aging 1994; 5: 335-345. Go to original source... Go to PubMed...
    22. Sussman N. Treatment of anxiety with buspirone. Psychiatric An 1987; 17, 114-118. Go to original source...
    23. Sussman N. Switching patients from benzodiazepines to buspirone. Drug therapy 1990; (suppl): 58-65.
    24. Vaškovský R. Improvment of mental diseases with anxiety symptoms by treatment with buspirone. CINP, Budapest, 25th-29th September 2001.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.